ESMO Virtual Congress 2020 Bladder Cancer

Viewing 1-20 of 34 articles

ESMO Virtual Congress 2020: Nivolumab Alone or in Combination with Ipilimumab in Patients with Platinum-Pretreated Metastatic Urothelial Carcinoma: Extended Follow-Up from CheckMate 032

ESMO Virtual Congress 2020: Molecular Profiling of Post-pembrolizumab Muscle-Invasive Bladder Cancer Reveals Unique Features That May Inspire New Sequential Therapies in Pathological Non-responders

ESMO Virtual Congress 2020: Real-World Evidence of the Impact of Prior Autoimmune Disease on Immune Checkpoint Inhibitor Outcomes in Patients with Metastatic Urothelial Cancer

ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 3: Sacituzumab Govitecan and Pembrolizumab in Patients with Progression or Recurrence of Metastatic Urothelial Cancer after Platinum -Based Therapy

ESMO Virtual Congress 2020: EV-302: Enfortumab Vedotin plus Pembrolizumab and/or Chemotherapy, vs Chemotherapy Alone, in Untreated Locally Advanced or Metastatic Urothelial Cancer

ESMO Virtual Congress 2020: Association Between Gene Expression Signatures and Pembrolizumab Efficacy in Patients with Advanced Urothelial Cancer

ESMO Virtual Congress 2020: Prognostic Factors Related to Post-Platinum Atezolizumab for Relapsed Metastatic Urothelial Cancer From the SAUL Study

ESMO Virtual Congress 2020: The Landscape is Moving in Metastatic Urothelial Carcinoma - Invited Discussant

ESMO Virtual Congress 2020: Invited Discussant: Optimizing First-Line Treatment in Metastatic Urothelial Carcinoma: Is the Fog Clearing?

ESMO Virtual Congress 2020: Patient-Reported Outcomes from IMvigor130: A Global, Randomised, Partially Blinded Phase III Study of Atezolizumab + Platinum-Based Chemotherapy vs. Placebo + PBC in Previously Untreated Locally Advanced or Metastatic Urothelia

ESMO Virtual Congress 2020: Avelumab First-Line Maintenance + Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma: Association Between Clinical Outcomes and Exploratory Biomarkers

ESMO Virtual Congress 2020: Unresectable or Metastatic Urothelial Carcinoma and Advanced Urothelial Carcinoma - Invited Discussant

ESMO Virtual Congress 2020: Sitravatinib in Combination with Nivolumab Demonstrates Clinical Activity In Checkpoint Inhibitor Naïve, Platinum-Experienced Patients with Advanced or Metastatic Urothelial Carcinoma

ESMO Virtual Congress 2020: Efficacy and Safety of Avelumab with Gemcitabine/Carboplatin (CG) vs CG Alone in Patients with Unresectable or Metastatic Urothelial Carcinoma Who are Ineligible to Receive Cisplatin-Based Therapy

ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan in Metastatic Urothelial Cancer that Has Progressed After Platinum and Checkpoint Inhibitors

ESMO 2020 Virtual Congress: Avelumab First-Line Maintenance + Best Supportive Care vs. BSC Alone with 1L Chemotherapy for Advanced Urothelial Carcinoma: Subgroup Analyses from JAVELIN Bladder 100

ESMO Virtual Congress 2020: Invited Discussant Bladder Cancer (PROs from IMvigor130, Biomarker Exploratory Analyses for Correlates of Overall Survival in JAVELIN Bladder 100, and Updated Cohort 1 Data for Sacituzumab Govitecan in mUC

ESMO Virtual Congress 2020: Pembrolizumab Combined With Chemotherapy vs. C Alone As First-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-361

ESMO Virtual Congress 2020: Avelumab First Line Maintenance + Best Supportive Care vs BSC Alone for Advanced Urothelial Carcinoma: Association between Clinical Outcomes and Exploratory Biomarkers

ESMO Virtual Congress 2020: The Efficacy and Safety of Avelumab with Gemcitabine/Carboplatin vs CG Alone in Patients with Unresectable or Metastatic Urothelial Carcinoma Who Are Ineligible to Receive Cisplatin-Based Therapy

1
2